Photoswitchable Probes of Oxytocin and Vasopressin.
Wirth U, Raabe K, Kalaba P, Keimpema E, Muttenthaler M, König B.
J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.3c01415 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för atosiban. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
10 träffarA preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.
Sutherland JJ, Yonchev D, Fekete A, Urban L.
Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists.
Katte TA, Reekie TA, Werry EL, Jorgensen WT, Boyd R, Wong ECN, Gulliver DW, Connor M, Kassiou M.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.05.013A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
Toxicol Sci · journal article · DOI 10.1093/toxsci/kft176Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
Bellenie BR, Barton NP, Emmons AJ, Heer JP, Salvagno C.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.11.064The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2007.11.008Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Fragiadaki M, Magafa V, Borovicková L, Slaninová J, Cordopatis P.
Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2006.12.0162,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
Borthwick AD, Davies DE, Exall AM, Hatley RJ, Hughes JA, Irving WR, Livermore DG, Sollis SL, Nerozzi F, Valko KL, Allen MJ, Perren M, Shabbir SS, Woollard PM, Price MA.
J Med Chem · journal article · DOI 10.1021/jm060073eDiscovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Quattropani A, Dorbais J, Covini D, Pittet PA, Colovray V, Thomas RJ, Coxhead R, Halazy S, Scheer A, Missotten M, Ayala G, Bradshaw C, De Raemy-Schenk AM, Nichols A, Cirillo R, Tos EG, Giachetti C, Golzio L, Marinelli P, Church DJ, Barberis C, Chollet A, Schwarz MK.
J Med Chem · journal article · DOI 10.1021/jm050645fPyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Failli AA, Shumsky JS, Steffan RJ, Caggiano TJ, Williams DK, Trybulski EJ, Ning X, Lock Y, Tanikella T, Hartmann D, Chan PS, Park CH.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2005.10.107